Descripción de la oferta
Specialized Laboratory Technician at Cancer Genomics Laboratory
Reference: 2026-022-01
Application deadline: 13/04/2026
Number of vacancies: 1
Job Description
The Cancer Genomics Group (PI: Ana Vivancos) is the Genomics Core Technology laboratory at VHIO. Our laboratory provides access to a range of cutting‑edge applications and technologies in cancer genomics, including NextGen Sequencers, MiSeq, NextSeq 550 (2 units) and NovaSeq 6000 (Illumina), and a ddPCR (BioRad). We provide cutting‑edge applications in cancer genomics through state‑of‑the‑art technologies and, importantly, the development of novel fully validated tests. Our novel genomic tests provide an important added value to our activity as a facility and research group, and to VHIO as a whole, enabling routine patient testing in the clinical research setting (Prescreening Program) as well as in translational research.
VHIO’s Prescreening Program is a transversal program nucleated around the activity of two VHIO groups – the Molecular Oncology (led by Paolo Nuciforo) and Cancer Genomics labs, performing routine molecular profiling in over 1500 patients per year. Patients included in the program are candidates for enrollment in Phase I clinical trials carried out at the Research Unit for Molecular Therapy of Cancer (UITM) – “la Caixa”, led by Elena Garralda. Patients’ suitability for inclusion in any given clinical trial is decided taking into account their respective genomic or pathologic profile.
The Cancer Genomics Lab has developed and implemented several tests during the last 10 years that have been in use in the Prescreening Program routine. Presently, a custom 435‑gene hybrid capture panel (VHIO-300, developed in 2018) is the DNA‑based test for tissue analysis. Recently, we developed a custom RNA seq panel (VHIO Epsilon ɛ00) for gene fusion detection and gene expression profiling analysis, including a gene expression signature reporting on IFNg-mediated inflammation (VIGex). In 2022, we completed the technical transfer of the FDA-approved Guardant360® CDx liquid biopsy test for comprehensive genomic profiling. Our lab is the first cancer research centre in Europe to have a laboratory equipped with this cutting‑edge platform.
As a reflection of our dedication to excellence and quality in the services we provide, both NGS‑DNA based tests have been accredited according to the UNE‑EN ISO 15189 quality system, that specifies requirements for quality and competence in medical laboratories. In recognition to our track, VHIO-300’s UNE‑EN ISO 15189 accreditation was awarded in its flexible version, allowing us to include new analytes directly in the accredited test (following a standard operating procedure).
Responsibilities
Nucleic acid extraction of fresh/frozen, plasma and FFPE samples.
Library preparation for NGS (Illumina-based), ddPCR, qPCR and RT‑qPCR, etc.
Assisting in the development of new applications in NGS for molecular profiling of cancer patients.
Requirements
Experience: At least 4 years of relevant laboratory experience in molecular biology and/or genomics techniques.
Studies: Ph.D., B.Sc or M.Sc will be considered an asset, although is not mandatory.
Languages: fluency in English is required.
Computer literacy is essential.
Benefits
